Sept 18 (Reuters) - Nabriva Therapeutics Plc shares more than doubled in premarket trading on Monday after the company said its experimental antibiotic for community-acquired bacterial pneumonia met the main goal of a late-stage study.
The clinical trial, which was the first of two late-stage studies, showed that the company's drug, lefamulin, was as effective as the commonly used antibiotic moxifloxacin, meeting the main goal of the trial.
Community-acquired bacterial pneumonia is one of the most common infectious diseases and the leading cause of infectious death in the United States.
The company's shares jumped to $13.91 in premarket trading from their Friday close of $6.86. (Reporting by Manas Mishra in Bengaluru; Editing by Anil D'Silva)